Brainsway has received investigational device exemption approval from the US Food and Drug Administration (FDA) to initiate a multicentre clinical trial to investigate the efficacy of its deep transcranial magnetic stimulation device as a treatment for bipolar disorder.
The device enables non-invasive depolarisation or hyperpolarisation of brain neurons.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial will involve on 120 patients at nine medical centres.
